Barry E. Greene

President at Alnylam Pharmaceuticals, Inc.

Barry E. Greene

Barry E. Greene

President at Alnylam Pharmaceuticals, Inc.

Overview
Career Highlights

Alnylam Pharmaceuticals, Inc.
Vicarious Surgical, Inc.

RelSci Relationships

2809

Number of Boards

7

Birthday

1964

Age

56

Contact Data
Trying to get in touch with Barry E. Greene? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Barry E. Greene likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Karyopharm Therapeutics, Inc.

Relationship likelihood: Strong

Executive Vice President, Chief Legal Officer & Secretary at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Vice President of Research & RLD at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder, Chief Technology Officer at Vicarious Surgical, Inc.

Relationship likelihood: Strong

Founder & Chief Executive Officer at Vicarious Surgical, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Barry E. Greene
Potential Connections via
Relationship Science
You
Barry E. Greene
President at Alnylam Pharmaceuticals, Inc.
Education
BS in Industrial Engineering

The University of Pittsburgh is among the nation's oldest and most distinguished comprehensive universities, with a wide variety of high-quality programs in the arts and sciences as well as professional fields. Pitt is a member of the Association of American Universities (AAU), which comprises 62 preeminent doctorate-granting research institutions in North America

Boards & Committees
Lead Independent Director
2013 - Current

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Member, Board of Directors
2007 - Current

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Member, Management Board
Current

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Political Donations
$1,000
2010

Government Affairs at Pax Labs, Inc.

Investments
Details Hidden

Ambrx, Inc. operates as a biopharmaceutical company, which engages in discovering and developing protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Barry E. Greene. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Barry E. Greene's profile does not indicate a business or promotional relationship of any kind between RelSci and Barry E. Greene.